Tag Archives | Pharmaceutical Industry

Study finds that financial parasitism contributes to the high cost of drugs

By Nick Bearns (originally published by World Socialist Web Site) - An article published in the New York Times on Friday, authored by business and finance journalist Gretchen Morgenson, on the pharmaceutical industry and US drug prices, points to one of the most significant economic phenomena of the present day—the rise of financial parasitism… [Cross-posted from World Socialist Web Site […]

Continue Reading 0

Il modello di business dei big pharma negliUsa

By Barbara De Amicis (originally published by RAI) - L’impresa farmaceutica, racchiusa sotto il nome di Big Pharma, sono l’oggetto di interesse della teoria dell’impresa innovativa di William Lazonick, economista dell’Università del Massachusetts a Lowell. Negli Stati Uniti, sottolinea Lazonick, le medicine costano il doppio e l’industria farmaceutica giustifica questo parlando di investimento in innovazione per produrre medicine per […]

Continue Reading 0

Prezzialtissimi, speculazione, zero ricera: Fermiano le industriefarmaceutiche

  By Fabrizio Patti (originally published by Linkiesta Weekend) – L’attività di comprare azioni proprie, da parte delle aziende, sarebbe considerata un’attività normale dal 99% degli economisti. Ma non certo da William Lazonick, che vieterebbe la pratica domani stesso, fosse per lui. Lo farebbe per tutte le società quotate, ma in particolare per le aziende farmaceutiche, quelle […]

Continue Reading 0

UK political parties promise science funding boost

By Daniel Cressey (Originally published by Nature) - UK scientists worried about how Brexit will affect their funding received a boost this week, when the country’s three main national parties pledged long-term targets to raise research spending. The announcements came in party manifestos unveiled ahead of national elections in June…. [Cross-posted from Nature publication of May 19, 2017 […]

Continue Reading 0

Shark attack: Pharmaceutical industry’s feeding frenzy

By The Institute for Health and Socio-Economic Policy (originally published by The Institute for Health and Socio-Economic Policy) - Throughout the series of briefs we have seen how pharmaceutical companies charge high drug prices1, enabling these companies to realize enormous profits.2 Through patents3 as well mergers and acquisitions4 they have created a market structure that allows them […]

Continue Reading 0

Outrageous fortunes: Pharma executives cash-in on high drug prices

By The Institution for Health and Socio-Economic Policy (originally published by The Institution for Health and Socio-Economic Policy) - The previous IHSP briefs explained why prices for prescription drugs have risen,1 and how these increases result in tremendous sales and profits.2 Pharmaceutical executives are paid to make sure that this is the case. The pay incentives […]

Continue Reading 0

Rx for excess: The truth behind Big Pharma spending

By Eric Reguly (originally published by Globe and Mail) - Presidential candidates Hillary Clinton, Bernie Sanders and Donald Trump were outraged last fall when Turing Pharmaceuticals jacked up the price of Daraprim, a drug used to fight parasitic infections often found in AIDS patients, to $750 (all currency in U.S. dollars) a pill from $13.50. Yes, […]

Continue Reading 0

How taxpayers prop up Big Pharma, and how to cap that

By Mariana Mazzucato (originally published by Los Angeles Times) – When Martin Shkreli of Turing Pharmaceuticals raised the price for Daraprim by 5,455%, he put drug pricing on the agenda for the leading 2016 presidential candidates. Bernie Sanders is reported to have rejected Shkreli’s campaign donation, and Hillary Rodham Clinton came out with a plan […]

Continue Reading 0

Maximizing shareholder value is (literally) killing us

By Brian Callaci (originally published by Center for Population Economics) – We depend on the research and development efforts of pharmaceutical companies to develop treatments for the most dangerous diseases on the planet, but the largest of those companies appear more interested in financial engineering than creating lifesaving drugs…. [Cross-posted from Center for Popular Economics […]

Continue Reading 0

developed by bodhiWeb